Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to -$779,000.

  • Lyell Immunopharma's Change in Account Payables fell 37.15% to -$779,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 508.02%. This contributed to the annual value of -$3.2 million for FY2024, which is 320.90% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Change in Account Payables stood at -$779,000, which was down 237.23% from -$231,000 recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Change in Account Payables peaked at $2.9 million during Q1 2022, and registered a low of -$2.0 million during Q4 2024.
  • Over the past 3 years, Lyell Immunopharma's median Change in Account Payables value was -$517,000 (recorded in 2024), while the average stood at -$403,091.
  • As far as peak fluctuations go, Lyell Immunopharma's Change in Account Payables skyrocketed by 363.25% in 2022, and later tumbled by 6,230.43% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Change in Account Payables (Quarterly) stood at $99,000 in 2021, then slumped by 631.31% to -$526,000 in 2022, then skyrocketed by 180.80% to $425,000 in 2023, then slumped by 579.06% to -$2.0 million in 2024, then slumped by 37.15% to -$779,000 in 2025.
  • Its Change in Account Payables stands at -$779,000 for Q3 2025, versus -$231,000 for Q2 2025 and -$1.7 million for Q1 2025.